A study from the 2022 lecture series of the International Network of Fatty Acid Oxidation Research and Management (INFORM) by Kathryn Ray, PhD, showed that triheptanoin improves left ventricular function in patients with LCFAOD with 55% or less ejection fraction.
It is known that LCFAOD can cause unpredictable cardiomyopathic events that could be life threatening. This treatment is approved by the FDA for both children and adults and is sold as Dojolvi® . This is the first and only medicine to treat long-chain fatty acid oxidation disorders.
Read more of the article here.